Other cardiometabolic health — Revenue
Eli Lilly Other cardiometabolic health — Revenue decreased by 11.0% to $905.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.2%, from $945.00M to $905.00M. Over 3 years (FY 2022 to FY 2025), Other cardiometabolic health — Revenue shows an upward trend with a 100.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful lifecycle management or market penetration of secondary therapeutic assets, while a decrease may suggest product maturity, increased competition, or a strategic shift in portfolio focus.
Detailed definition
This metric represents the total net sales generated from the company's secondary portfolio of cardiometabolic therapeut...
Peer comparison
Comparable to secondary metabolic or cardiovascular product line revenues reported by major pharmaceutical peers, often categorized under 'established products' or 'specialty care' segments.
lly_segment_other_cardiometabolic_health_revenueHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $124.23M | $124.23M | $124.23M | $124.23M | $113.50M | $136.60M | $141.90M | $4.06B | $1.03B | $1.17B | $1.05B | $1.22B | $945.00M | $980.40M | $1.06B | $1.02B | $905.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -8.6% | +20.4% | +3.9% | >999% | -74.7% | +13.6% | -10.0% | +16.3% | -22.5% | +3.7% | +8.5% | -4.4% | -11.0% |
| YoY Change | — | — | — | — | -8.6% | +10.0% | +14.2% | >999% | +804.2% | +753.1% | +639.0% | -70.0% | -7.9% | -15.9% | +1.4% | -16.6% | -4.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other cardiometabolic health — revenue?
- Eli Lilly (LLY) reported other cardiometabolic health — revenue of $905.00M in Q1 2026.
- How has Eli Lilly's other cardiometabolic health — revenue changed year-over-year?
- Eli Lilly's other cardiometabolic health — revenue decreased by 4.2% year-over-year, from $945.00M to $905.00M.
- What is the long-term trend for Eli Lilly's other cardiometabolic health — revenue?
- Over 3 years (2022 to 2025), Eli Lilly's other cardiometabolic health — revenue has grown at a 100.5% compound annual growth rate (CAGR), from $496.90M to $4.01B.
- What does other cardiometabolic health — revenue mean?
- The total revenue generated by the company's secondary or niche cardiometabolic health pharmaceutical products.